Inhalation Sciences Sweden AB Stock
Stocks
ISAB
SE0009983893
Advanced Medical Equipment & Technology
OTC Markets Traded|
End-of-day quote
SPOTLIGHT STOCK MARKET AB
30/09/2026
|
5-day change | 1st Jan Change | ||
| 0.0810 SEK | -.--% |
|
-.--% | -98.13% |
| 21/10 | Inhalation Sciences enters strategic collaboration with Lovelace Biomedical | FW |
| 16/10 | Inhalation Sciences plans SEK 10m rights issue | FW |
| Market Cap | 4.15M 420K 376K 344K 314K 592K 39.46M 610K 1.65M 21.05M 1.58M 1.54M 66.46M | P/E 2024 |
-12.8x | P/E 2025 | -12.4x |
|---|---|---|---|---|---|
| Enterprise Value | 1.32M 133K 119K 109K 99.66K 188K 12.52M 194K 525K 6.68M 500K 489K 21.09M | EV / Sales 2024 |
5.6x | EV / Sales 2025 | 55x |
| Free-Float |
99.4% | Yield 2024 * |
-
| Yield 2025 | - |
| 3 months | -55.12% | ||
| 6 months | -65.53% | ||
| Current year | -98.13% |
| Current year | 0.06 |  | 0.58 |
| 1 year | 0.06 | | 0.58 |
| 3 years | 0.06 | | 4.99 |
| 5 years | 0.06 | | 10.95 |
| 10 years | 0.06 | | 15.48 |
| Manager | Title | Age | Since |
|---|---|---|---|
Manoush Masarrat
CEO | Chief Executive Officer | - | 16/09/2019 |
Per Magnus Gerde
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/2005 |
Ulf Wedenberg
PRN | Corporate Officer/Principal | - | 02/06/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Per Magnus Gerde
BRD | Director/Board Member | - | 01/01/2005 |
Jan Hellqvist
BRD | Director/Board Member | - | 01/09/2022 |
Ulf Ericsson
BRD | Director/Board Member | - | 01/09/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | -98.13% | -98.02% | 424K | |
| +2.63% | -0.32% | +22.75% | +52.69% | 251B | |
| -3.36% | +4.81% | -17.34% | +63.31% | 162B | |
| +1.73% | -0.85% | +9.29% | +17.76% | 159B | |
| -4.23% | +1.83% | -56.84% | -19.05% | 64.7B | |
| +1.31% | +11.01% | +23.90% | +52.22% | 57.97B | |
| -0.76% | +4.13% | +0.84% | -6.12% | 56.21B | |
| -2.05% | -2.95% | +4.30% | +54.85% | 50.21B | |
| +1.73% | -0.06% | +18.49% | +62.52% | 48.43B | |
| +1.00% | -1.11% | +23.29% | +81.48% | 44.51B | |
| Average | -0.20% | +0.09% | -6.95% | +26.16% | 89.45B | |
| Weighted average by Cap. | +0.19% | +1.29% | +4.78% | +41.57% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 11.05M 1.12M 1M 916K 837K 1.58M 105M 1.63M 4.4M 56.08M 4.2M 4.11M 177M | 3.04M 308K 276K 252K 230K 434K 28.93M 448K 1.21M 15.44M 1.16M 1.13M 48.74M |
| Net income | -5.15M -521K -467K -427K -390K -734K -48.97M -758K -2.05M -26.13M -1.96M -1.91M -82.49M | -10.16M -1.03M -922K -843K -769K -1.45M -96.66M -1.5M -4.05M -51.58M -3.86M -3.78M -163M |
| Net Debt | -4M -405K -363K -332K -303K -571K -38.09M -589K -1.6M -20.32M -1.52M -1.49M -64.15M | -2.83M -287K -257K -235K -214K -404K -26.93M -417K -1.13M -14.37M -1.08M -1.05M -45.37M |
Employees
5
Net sales - Rate of surprise
- Stock Market
- Stocks
- ISAB Stock
Select your edition
All financial news and data tailored to specific country editions
